Up next

Autoplay

Checkpoint Inhibitors in Malignant Pleural Mesothelioma

0 Views • 07/02/23
Share
Embed
administrator
administrator
Subscribers
0

Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay